IMPOYZ

Peak

clobetasol propionate

NDATOPICALCREAM
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown. The contribution to efficacy by individual components of the vehicle has not been established.

Indications (4)

moderate to severe plaque psoriasis in patients 18 years of ageolderolder ()psoriasis

Clinical Trials (5)

NCT05724446Phase 3Recruiting

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Started Dec 2022
60 enrolled
Cataracts Infantile
NCT04246801Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

Started Jun 2020
250 enrolled
Cataract
NCT04249076Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Started Jun 2020
215 enrolled
Cataract
NCT01323673Phase 4Completed

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Started Nov 2010
125 enrolled
Dermatitis, Chronic
NCT00828464Phase 4Completed

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

Started Oct 2008
30 enrolled
Hand Dermatosis

Loss of Exclusivity

LOE Date
Mar 11, 2035
109 months away
Patent Expiry
Mar 11, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
10064875
Aug 31, 2030
Product
U-742
10588914
Aug 31, 2030
Product
U-2771
11179465
Aug 31, 2030
Product
U-1858
9956231
Aug 31, 2030
Product
U-1761
9855334
Mar 11, 2035
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers